Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The selective 5-HT1A receptor biased agonist, NLX-101, corrects anomalous behavioral phenotype in a mouse model of fragile X syndrome.

Progress in neuro-psychopharmacology & biological psychiatry - 2 Apr 2026

Depoortère Ronan, Tranfaglia Michael R, Newman-Tancredi Adrian

Abstract excerpt

Fragile X syndrome (FXS) is the most prevalent X-linked dominant autism spectrum disorder, causing a range of developmental problems, notably characterized by mild-severe mood/cognitive dysfunctions. NLX-101 is a highly selective and fully efficacious biased agonist at post-synaptic 5-HT1A receptors, and has shown efficacy for reversal of sensory hypersensitivity and EEG anomalies in transgenic mouse models of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dose-Response Relationship, Drug
Share to Fragile X Syndrome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Inbred C57BL

Share to Mice, Knockout

Share to Mice, Transgenic

Share to Motor Activity

Share to Piperazines

Share to Receptor, Serotonin, 5-HT1A

Source

Identifiers

PMID: 41875967
DOI: 10.1016/j.pnpbp.2026.111681

Genes

FMR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The selective 5-HT1A receptor biased agonist, NLX-101, corrects anomalous behavioral phenotype in a mouse model of fragile X syndrome.PMID 41875967Read ↗

The selective 5-HT <sub>1A</sub> receptor biased agonist, NLX-101, corrects anomalous behavioral phenotype in a mouse model of Fragile X syndromeSemantic proximity Read ↗

Effects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: neurobehavioral phenotypes and receptor occupancy.Semantic proximity Read ↗

Effects of the Sigma-1 Receptor Agonist Blarcamesine in a Murine Model of Fragile X Syndrome: Neurobehavioral Phenotypes and Receptor OccupancySemantic proximity Read ↗

Vorinostat corrects cognitive and non-cognitive symptoms in a mouse model of fragile X syndromeSemantic proximity Read ↗

A suite of engineered mice for interrogating psychedelic drug actionsSemantic proximity Read ↗

Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by a BKCa channel opener molecule.Semantic proximity Read ↗

The psychiatric presentation of fragile x: evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndrome.Semantic proximity Read ↗

Behavioral, neurotransmitter and transcriptomic analyses in male and female Fmr1 KO miceSemantic proximity Read ↗

Drug-responsive autism phenotypes in the 16p11.2 deletion mouse model: a central role for gene-environment interactions.Semantic proximity Read ↗

Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.Semantic proximity Read ↗

Multiple Behavior Phenotypes of the Fragile-X Syndrome Mouse Model Respond to Chronic Inhibition of Phosphodiesterase-4D (PDE4D).Semantic proximity Read ↗

A serotonergic mechanism is involved in the pro-cognitive effect of AM6545 treatment in a mouse model of fragile X syndromeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.